<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00402649</url>
  </required_header>
  <id_info>
    <org_study_id>06-0072</org_study_id>
    <nct_id>NCT00402649</nct_id>
  </id_info>
  <brief_title>Open-Label Study of H5 Vaccine in Participants of Protocol 04-077</brief_title>
  <official_title>Open-Label Study of Intramuscular Inactivated Influenza A/H5N1 Vaccine in Healthy Children Aged 2 Years to 10 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      This study may provide safety information on a flu vaccine given to children and may provide
      immunogenicity information to add to what was collected in a previous flu vaccine study.
      Participants will include 55 healthy children, ages 2-10, who participated in 04-077 and
      received a placebo injection instead of the flu vaccine or were incompletely immunized. The
      study has 2 purposes: to make sure there are no serious side effects in children and to see
      how the immune systems react to the vaccine. Study procedures include up to 4 study visits,
      up to 9 follow-up phone calls, 2 blood samples to be collected during visits 1 and 3, and up
      to 3 vaccine injections in the arm or thigh muscle. Parents will be given a memory aid card
      to record side effects, temperatures, and medications. Parents will have the option for the
      child to receive a 3rd dose of vaccine if offered, at month 6. This booster shot will require
      a 6-month visit and participation for an additional 6 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The recent emergence of novel influenza virus strains in human populations has encouraged
      efforts to develop vaccines for a potential pandemic. The objectives of this study are to
      evaluate the safety of intramuscular (IM) subvirion inactivated H5N1 vaccine in healthy
      children aged 2 through 10 years and to determine the immunogenicity profile of IM subvirion
      inactivated H5N1 vaccine in healthy children approximately 1 month following receipt of the
      second of 2 doses of vaccine. Study endpoints include: adverse event (AE) and serious adverse
      event (SAE) information (solicited in-clinic and via memory aids, concomitant medications,
      and periodic targeted physical assessments, as indicated); proportion of subjects achieving a
      serum hemagglutination inhibition antibody titer of 1:40 against the influenza A/H5N1 virus
      28 days after receipt of second dose of vaccine (approximately Day 56); geometric mean titer
      and the frequency of 4-fold or greater increases in hemagglutination inhibition antibody
      titers 28 days after receipt of second dose of vaccine (approximately Day 56); and
      development of serum antibody responses against antigenically drifted variants of influenza
      H5N1 virus. This study is linked to DMID protocol 06-0072. Up to 55 healthy children, aged 2
      through 10 years, who previously participated in DMID 04-077, will be eligible for enrollment
      in this multimember, open-label, phase I/II clinical trial to receive at least 2 and up to 3
      doses of an inactivated influenza A/H5N1 vaccine at a 45-micrograms dose. The vaccine dosage
      level that will be used in this study was chosen based upon safety and immunogenicity data
      collected previously in adults and children. The injection volume of the 90-micrograms dose
      is 1 mL for the vaccine being used in this study, but this is considered unacceptable in this
      age group. Therefore, the 45-micrograms dose (0.5 ml volume) has been selected. Twenty three
      subjects who were previously enrolled and assigned to placebo in the DMID 04-077 study (A
      Randomized, Double-Blinded, Placebo-Controlled, Phase I/II, Study of the Safety,
      Reactogenicity, and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine in
      Healthy Children Aged 2 Years Through 9 Years) along with up to 32 subjects from a single
      site who were incompletely immunized are eligible for enrollment in this study. Vaccine will
      be administered into the deltoid or (if age appropriate) thigh muscle. All subjects will
      receive 2 doses of the vaccine approximately 28 days apart. At month 6, subjects' parent(s)
      or guardian(s) will be called to assess the subjects for serious adverse events. Blood
      collection for immunogenicity studies will be at the discretion of the parent(s) or legal
      guardian(s). Should data evaluating a third dose of the influenza A/H5N1 vaccine show
      enhanced immunogenicity in pediatric subjects participating in DMID 04-077, parents/guardians
      of subjects who received vaccine will be offered the possibility of a third dose for their
      participating children.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Solicited Adverse Events Among All Subjects</measure>
    <time_frame>Days 0-7 post each vaccination</time_frame>
    <description>Number of subjects reporting solicited Adverse Events collected on Memory Aid for Days 0-7 post each vaccination for all subjects (systematic assessment), for any and severe severities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of the Solicited Adverse Event of Body Aches, Solicited Only From Children Age 6-10</measure>
    <time_frame>Days 0-7 post each vaccination</time_frame>
    <description>Number of subjects reporting solicited Adverse Event of Body Aches, collected on Memory Aid for Days 0-7 post each vaccination for children age 6-10 only (systematic assessment), of any and severe severities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Unsolicited Adverse Events</measure>
    <time_frame>Through Day 28 after second vaccination</time_frame>
    <description>Number of subjects with spontaneous reports of Adverse Events of any and severe severities. Events reported by more than 5.6% of subjects in any group are reported by MedDRA Preferred Term.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Serious Adverse Events</measure>
    <time_frame>6 months after the first vaccination</time_frame>
    <description>Number of subjects with Serious Adverse Events during the 6 months after the first vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Titers of 1:40 or Greater</measure>
    <time_frame>Day 28 after second vaccination</time_frame>
    <description>Number of subjects achieving serum hemagglutination inhibition antibody titer of 1:40 or greater against the influenza A/H5N1 virus after receipt of two doses of vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer of Hemagglutination Inhibition Antibody Titers</measure>
    <time_frame>Day 28 after second vaccination</time_frame>
    <description>Geometric mean titer of hemagglutination inhibition antibody titers after receipt of two doses of vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Four-fold or Greater Increase in Hemagglutination Inhibition Antibody Titers</measure>
    <time_frame>Day 28 after second vaccination</time_frame>
    <description>Number of subjects with a 4-fold or greater increase, relative to baseline, in hemagglutination inhibition antibody titers after receipt of two doses of vaccine.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive at least 2 and up to 3 doses of the vaccine approximately 28 days apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)</intervention_name>
    <description>Inactivated influenza A/H5N1 vaccine administered via intramuscular (IM) injection; dosage 45-mcg.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject must be male or female, aged 2 through 10 years at enrollment, and must
             have participated in protocol 04-077 as a placebo recipient or a subject at the UCLA
             site.

          -  The subject must be in good health (and not on any chronic medications), as determined
             by medical history and a history-directed targeted physical examination.

          -  Parents or guardians of the subject must be able to understand and comply with planned
             study procedures and be available for all study visits.

          -  Parents or guardians of the subject must provide written consent prior to initiation
             of any study procedures, and subject may provide written assent as appropriate.

        Exclusion Criteria:

          -  The subject must not have a known allergy to eggs or other components of the vaccine
             or sensitivity or allergy to latex.

          -  The subject must not have a history of asthma or recurrent wheezing.

          -  The subject must not be undergoing immunosuppression as a result of an underlying
             illness or treatment.

          -  The subject must not have an active neoplastic disease or a history of any hematologic
             malignancy.

          -  The subject must not be using oral or parenteral steroids, inhaled steroids, or other
             immunosuppressive or cytotoxic drugs. Note: Subjects on nasal or topical steroids will
             be allowed to enroll in this study.

          -  The subject must not have a history of receiving immunoglobulin or other blood product
             within the 3 months prior to enrollment in this study.

          -  The subject must not receive any other inactivated vaccines within 2 weeks before or
             after any study vaccine or any other live vaccines within 4 weeks before or after any
             study vaccine in this study.

          -  The subject must not have an acute or chronic medical condition that, in the opinion
             of the investigator, would render vaccination unsafe or would interfere with the
             evaluation of responses (these conditions include, but are not limited to, known
             chronic liver disease, significant renal disease, unstable or progressive neurological
             disorders, diabetes mellitus, and transplant recipients).

          -  The subject must not have a history of severe reactions following immunization with
             contemporary influenza virus vaccines.

          -  The subject must not have an acute illness, including an axillary temperature greater
             than or equal to 100 degrees F or an oral temperature greater than or equal to 101
             degrees F within 3 days prior to vaccination.

          -  The subject must not have received an experimental vaccine or medication within 1
             month prior to enrollment in this study, or expect to receive an experimental vaccine,
             medication, or blood product during the 13-month study period.

          -  The subject must not have any condition that would, in the opinion of the
             investigator, place them at an unacceptable risk of injury or render the subject
             unable to meet the requirements of the protocol.

          -  The subject must not have a history of Guillain-Barré syndrome.

          -  The subject must not be participating concurrently in another clinical trial aside
             from DMID 04-077 (either in active phase or in follow-up phase).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCLA Center For Vaccine Research</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2006</study_first_submitted>
  <study_first_submitted_qc>November 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2006</study_first_posted>
  <results_first_submitted>October 16, 2008</results_first_submitted>
  <results_first_submitted_qc>November 20, 2008</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 24, 2008</results_first_posted>
  <last_update_submitted>June 9, 2011</last_update_submitted>
  <last_update_submitted_qc>June 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, ORA</name_title>
    <organization>HHS/NIAID/DMID</organization>
  </responsible_party>
  <keyword>influenza, A/H5N1, avian influenza, vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was offered to the 23 subjects (aged 2-10 years) who were previously enrolled and assigned to placebo at the three clinical sites in the DMID 04-077 study (NCT00133536), along with up to 32 subjects from a single site who were incorrectly dosed in that study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Inactivated Influenza A/H5N1 Vaccine</title>
          <description>All subjects will receive at least 2 and up to 3 doses of the vaccine approximately 28 days apart.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Inactivated Influenza A/H5N1 Vaccine</title>
          <description>All subjects will receive at least 2 and up to 3 doses of the vaccine approximately 28 days apart.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.6" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Solicited Adverse Events Among All Subjects</title>
        <description>Number of subjects reporting solicited Adverse Events collected on Memory Aid for Days 0-7 post each vaccination for all subjects (systematic assessment), for any and severe severities.</description>
        <time_frame>Days 0-7 post each vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inactivated Influenza A/H5N1 Vaccine</title>
            <description>All subjects will receive at least 2 and up to 3 doses of the vaccine approximately 28 days apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Solicited Adverse Events Among All Subjects</title>
          <description>Number of subjects reporting solicited Adverse Events collected on Memory Aid for Days 0-7 post each vaccination for all subjects (systematic assessment), for any and severe severities.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Elevated Oral Temperature of any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated Oral Temperature - severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Activity of any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Activity - severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain of any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain - severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mobility of any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mobility - severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness of any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness - severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling of any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling - severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash of any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash - severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Titers of 1:40 or Greater</title>
        <description>Number of subjects achieving serum hemagglutination inhibition antibody titer of 1:40 or greater against the influenza A/H5N1 virus after receipt of two doses of vaccine.</description>
        <time_frame>Day 28 after second vaccination</time_frame>
        <population>Blood draw was optional - blood collected from 16 participants</population>
        <group_list>
          <group group_id="O1">
            <title>Inactivated Influenza A/H5N1 Vaccine</title>
            <description>All subjects will receive at least 2 and up to 3 doses of the vaccine approximately 28 days apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serum Hemagglutination Inhibition (HAI) Antibody Titers of 1:40 or Greater</title>
          <description>Number of subjects achieving serum hemagglutination inhibition antibody titer of 1:40 or greater against the influenza A/H5N1 virus after receipt of two doses of vaccine.</description>
          <population>Blood draw was optional - blood collected from 16 participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer of Hemagglutination Inhibition Antibody Titers</title>
        <description>Geometric mean titer of hemagglutination inhibition antibody titers after receipt of two doses of vaccine.</description>
        <time_frame>Day 28 after second vaccination</time_frame>
        <population>Blood draw was optional - blood collected from 16 participants</population>
        <group_list>
          <group group_id="O1">
            <title>Inactivated Influenza A/H5N1 Vaccine</title>
            <description>All subjects will receive at least 2 and up to 3 doses of the vaccine approximately 28 days apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer of Hemagglutination Inhibition Antibody Titers</title>
          <description>Geometric mean titer of hemagglutination inhibition antibody titers after receipt of two doses of vaccine.</description>
          <population>Blood draw was optional - blood collected from 16 participants</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" lower_limit="8.4" upper_limit="51.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Four-fold or Greater Increase in Hemagglutination Inhibition Antibody Titers</title>
        <description>Number of subjects with a 4-fold or greater increase, relative to baseline, in hemagglutination inhibition antibody titers after receipt of two doses of vaccine.</description>
        <time_frame>Day 28 after second vaccination</time_frame>
        <population>Blood draw was optional - blood collected from 16 participants post vaccination, but missing baseline assessment for 3 of 16 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Inactivated Influenza A/H5N1 Vaccine</title>
            <description>All subjects will receive at least 2 and up to 3 doses of the vaccine approximately 28 days apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Four-fold or Greater Increase in Hemagglutination Inhibition Antibody Titers</title>
          <description>Number of subjects with a 4-fold or greater increase, relative to baseline, in hemagglutination inhibition antibody titers after receipt of two doses of vaccine.</description>
          <population>Blood draw was optional - blood collected from 16 participants post vaccination, but missing baseline assessment for 3 of 16 subjects</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of the Solicited Adverse Event of Body Aches, Solicited Only From Children Age 6-10</title>
        <description>Number of subjects reporting solicited Adverse Event of Body Aches, collected on Memory Aid for Days 0-7 post each vaccination for children age 6-10 only (systematic assessment), of any and severe severities.</description>
        <time_frame>Days 0-7 post each vaccination</time_frame>
        <population>Solicited symptom of Body Aches was collected from subjects age 6-10 only</population>
        <group_list>
          <group group_id="O1">
            <title>Inactivated Influenza A/H5N1 Vaccine</title>
            <description>All subjects will receive at least 2 and up to 3 doses of the vaccine approximately 28 days apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of the Solicited Adverse Event of Body Aches, Solicited Only From Children Age 6-10</title>
          <description>Number of subjects reporting solicited Adverse Event of Body Aches, collected on Memory Aid for Days 0-7 post each vaccination for children age 6-10 only (systematic assessment), of any and severe severities.</description>
          <population>Solicited symptom of Body Aches was collected from subjects age 6-10 only</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Body Aches of any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Aches - severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Unsolicited Adverse Events</title>
        <description>Number of subjects with spontaneous reports of Adverse Events of any and severe severities. Events reported by more than 5.6% of subjects in any group are reported by MedDRA Preferred Term.</description>
        <time_frame>Through Day 28 after second vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inactivated Influenza A/H5N1 Vaccine</title>
            <description>All subjects will receive at least 2 and up to 3 doses of the vaccine approximately 28 days apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Unsolicited Adverse Events</title>
          <description>Number of subjects with spontaneous reports of Adverse Events of any and severe severities. Events reported by more than 5.6% of subjects in any group are reported by MedDRA Preferred Term.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vomiting of any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting - severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal viral of any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal viral - severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasopharyngitis of any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasopharyngitis - severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper respiratory tract infection of any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper respiratory tract infection - severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache of any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache - severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rhinitis allergic of any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rhinitis allergic - severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Serious Adverse Events</title>
        <description>Number of subjects with Serious Adverse Events during the 6 months after the first vaccination.</description>
        <time_frame>6 months after the first vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inactivated Influenza A/H5N1 Vaccine</title>
            <description>All subjects will receive at least 2 and up to 3 doses of the vaccine approximately 28 days apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Serious Adverse Events</title>
          <description>Number of subjects with Serious Adverse Events during the 6 months after the first vaccination.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subjects’ parents/guardians recorded solicited symptoms on a memory aid for 8 days (Day 0-7) following each dose. Unsolicited non-serious adverse events were collected for 28 days after each dose and serious adverse events were collected through Day 180.</time_frame>
      <desc>The solicited symptoms are reported separately after each vaccination. The occurrence of a solicited symptom on any day(s) at any severity within the 8 day period was considered one event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Inactivated Influenza A/H5N1 Vaccine</title>
          <description>All subjects will receive at least 2 and up to 3 doses of the vaccine approximately 28 days apart.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (9.1)">Vomiting</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - post dose 1</sub_title>
                <description>Solicited on the memory aid as &quot;Body aches&quot;, limited to subjects aged 6-10 years old</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pain - post dose 2</sub_title>
                <description>Solicited on the memory aid as &quot;Body aches&quot;, limited to subjects aged 6-10 years old</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.0)">Injection site erythema - post dose 1</sub_title>
                <description>Solicited on the memory aid as &quot;Redness&quot;, measured in millimeters</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.0)">Injection site erythema - post dose 2</sub_title>
                <description>Solicited on the memory aid as &quot;Redness&quot;, measured in millimeters</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (8.1)">Injection site swelling - post dose 1</sub_title>
                <description>Solicited on the memory aid as &quot;Swelling&quot;, measured in millimeters</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (8.1)">Injection site swelling - post dose 2</sub_title>
                <description>Solicited on the memory aid as &quot;Swelling&quot;, measured in millimeters</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.0)">Injection site pain - post dose 1</sub_title>
                <description>Solicited on the memory aid as &quot;Pain at injection site&quot;</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.0)">Injection site pain - post dose 2</sub_title>
                <description>Solicited on the memory aid as &quot;Pain at injection site&quot;</description>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Decreased activity - post dose 1</sub_title>
                <description>Solicited on the memory aid as &quot;General activity level&quot;</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Decreased activity - post dose 2</sub_title>
                <description>Solicited on the memory aid as &quot;General activity level&quot;</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (12.0)">Joint range of motion decreased - post dose 1</sub_title>
                <description>Solicited on the memory aid as &quot;Mobility of injection site limb&quot;</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Joint range of motion decreased - post dose 2</sub_title>
                <description>Solicited on the memory aid as &quot;Mobility of injection site limb&quot;</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (8.0)">Rhinitis allergic</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ina Stephens, MD</name_or_title>
      <organization>University of Maryland Center for Vaccine Development</organization>
      <phone>410-706-1123</phone>
      <email>istephen@medicine.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

